AlphaQuest LLC Reduces Stock Holdings in Celcuity, Inc. $CELC

Key Points

• AlphaQuest LLC reduced its stake in Celcuity, Inc. by 67.5% during the first quarter, now owning 2,565 shares valued at approximately $26,000.
• Celcuity has seen positive revisions from analysts, with Leerink Partners raising its price target from $28.00 to $60.00 and the company receiving an average rating of "Buy."
• Director David Dalvey significantly decreased his stake by selling 100,000 shares for about $4.4 million, now holding 125,000 shares valued at approximately $5.5 million.

AlphaQuest LLC reduced its stake in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 67.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,565 shares of the company's stock after selling 5,329 shares during the period. AlphaQuest LLC's holdings in Celcuity were worth $26,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC increased its holdings in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock worth $131,000 after purchasing an additional 1,225 shares in the last quarter. Gagnon Securities LLC increased its holdings in Celcuity by 3.5% during the 1st quarter. Gagnon Securities LLC now owns 54,310 shares of the company's stock worth $549,000 after purchasing an additional 1,831 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Celcuity by 16.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock worth $258,000 after purchasing an additional 2,756 shares in the last quarter. Rhumbline Advisers increased its holdings in Celcuity by 8.9% during the 1st quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock worth $427,000 after purchasing an additional 3,439 shares in the last quarter. Finally, EntryPoint Capital LLC increased its holdings in Celcuity by 18.4% during the 1st quarter. EntryPoint Capital LLC now owns 24,687 shares of the company's stock worth $250,000 after purchasing an additional 3,840 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director David Dalvey sold 100,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the transaction, the director owned 125,000 shares in the company, valued at approximately $5,497,500. This represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.78% of the company's stock.

Celcuity Stock Performance

Celcuity stock traded up $6.84 during trading on Monday, hitting $62.53. The stock had a trading volume of 1,452,257 shares, compared to its average volume of 892,075. Celcuity, Inc. has a 1 year low of $7.57 and a 1 year high of $62.92. The company has a quick ratio of 4.58, a current ratio of 4.58 and a debt-to-equity ratio of 2.24. The stock's 50 day moving average is $35.30 and its two-hundred day moving average is $19.27. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of -18.12 and a beta of 0.72.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). As a group, analysts predict that Celcuity, Inc. will post -2.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on CELC shares. HC Wainwright boosted their price objective on Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Needham & Company LLC cut their target price on Celcuity from $74.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Stifel Nicolaus assumed coverage on Celcuity in a research note on Tuesday, July 1st. They issued a "buy" rating and a $30.00 target price on the stock. Finally, Leerink Partners boosted their target price on Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, July 28th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $56.50.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.